PREOPERATIVE CHEMORADIATION FOR RECTAL CANCER USING CAPECITABINE AND CELECOXIB CORRELATED WITH POSTTREATMENT ASSESSMENT OF THYMIDYLATE SYNTHASE AND THYMIDINE PHOSPHORYLASE EXPRESSION

Basit Öğe Kaydı
dc.contributor.authorUnger, Keith R.
dc.contributor.authorRomney, Davis A.
dc.contributor.authorKoc, Mehmet
dc.contributor.authorMoskaluk, Christopher. A.
dc.contributor.authorFriel, Charles M.
dc.contributor.authorFoley, E. F.
dc.contributor.authorRich, Tyvin A.
dc.date.accessioned2020-03-26T18:15:44Z
dc.date.available2020-03-26T18:15:44Z
dc.date.issued2011
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractPurpose: Thymidylate synthase (TS) and thymidine phosphorylase (TP) expression have been shown to be predictors of response to therapy. The toxicity, efficacy, surgical morbidity, and immunohistochemical TS and TP expression were assessed in surgical resection specimens after preoperative chemoradiation. Methods and Materials: Twenty patients with clinical stage I to III rectal adenocarcinoma received preoperative chemoradiation and underwent surgical resection 6 weeks later. Results: Posttreatment tumor stages were T1 to T2 and N0 in 30% of patients; T3 to T4 and N0 in 30% of patients; and T1 to T3 and N1 to N2 in 15% of patients. Pathologic complete response (pCR) was evident in 25% and tumor regression occurred in a total of 80% of patients. Anal sphincter-sparing surgery was performed in 80% of cases. Acute and perioperative complications were minimal, with no grade 3/4 toxicity or treatment breaks. Pelvic control was obtained in 90% of patients. With a median follow-up of 65.5 months (range, 8-80 months), the 6-year actuarial survival rate was 75%. Local failure was significantly associated with nonresponse to therapy and with high TS and low TP expression (p = 0.008 and p = 0.04, respectively). Conclusions: The combination of capecitabine, celecoxib, and x-radiation therapy yields excellent response: a 25% pathologic pCR, no acute grade 3/4 toxicity, and minimal surgical morbidity. Nonresponders expressed significantly increased TS levels and decreased TP levels in posttreatment resection specimens compared to responders. (C) 2011 Elsevier Inc.en_US
dc.description.sponsorshipNIDDK NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [P30 DK067629]en_US
dc.identifier.doi10.1016/j.ijrobp.2010.04.016en_US
dc.identifier.endpage1382en_US
dc.identifier.issn0360-3016en_US
dc.identifier.issue5en_US
dc.identifier.pmid20656421en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage1377en_US
dc.identifier.urihttps://dx.doi.org/10.1016/j.ijrobp.2010.04.016
dc.identifier.urihttps://hdl.handle.net/20.500.12395/26742
dc.identifier.volume80en_US
dc.identifier.wosWOS:000293207600015en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherELSEVIER SCIENCE INCen_US
dc.relation.ispartofINTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICSen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectRectal canceren_US
dc.subjectChronomodulated chemoradiationen_US
dc.subjectThymidylate synthaseen_US
dc.subjectThymidine phosphorylaseen_US
dc.titlePREOPERATIVE CHEMORADIATION FOR RECTAL CANCER USING CAPECITABINE AND CELECOXIB CORRELATED WITH POSTTREATMENT ASSESSMENT OF THYMIDYLATE SYNTHASE AND THYMIDINE PHOSPHORYLASE EXPRESSIONen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu